Pfizer acquires Anacor
The converted shares won’t include interest but will be subject to mandatory withholding of taxes. On June 24, the two companies started their joint operations.
The company stated that the transaction won’t change the current 2016 adjusted financial guidance for Pfizer.
Pfizer anticipates the transaction will be slightly dilutive to Adjusted Diluted Earnings Per Share (EPS) in 2017 with accretion to Adjusted Diluted EPS beginning in 2018.
“Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease, an area of high unmet medical need,” Albert Bourla, Group President, Pfizer Innovative Health, said. “We believe that Pfizer is in a position to quickly capitalize on the benefits offered by the combination with Anacor, including the potential for a near-term U.S. product launch and subsequent commercialization of crisaborole, a differentiated asset with compelling clinical data. If approved, crisaborole has the potential to be an important first-line treatment option for patients with mild-to-moderate atopic dermatitis and the physicians who treat them.”